{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:43:41Z","timestamp":1789685021624,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la recherche sur le cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ligue Contre le Cancer (Ile de France committee)"},{"name":"Chancellerie des Universit\u00e9s de Paris (Legs POIX)"},{"DOI":"10.13039\/501100006431","name":"Canc\u00e9rop\u00f4le R\u00e9gion \u00cele-de-France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006431","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004792","name":"French Ministry of Higher Education and Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004792","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Chirurgie \u2013 Thoracique et Cardiovasculaire (SFCTV)"},{"name":"Institut th\u00e9matique multi-organismes (ITMO) Cancer"},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la recherche sur le cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Labex OncoImmunology (investissement d\u2019avenir)"},{"name":"Coup d\u2019Elan de la Fondation Bettencourt-Shueller"},{"name":"SIRIC CARPEM, the Institut th\u00e9matique multi-organismes (ITMO) Cancer"},{"DOI":"10.13039\/501100006431","name":"Canc\u00e9rop\u00f4le \u00cele-de-France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006431","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.lungcan.2018.10.015","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T16:35:15Z","timestamp":1539707715000},"page":"15-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5789-0153","authenticated-orcid":false,"given":"Robin","family":"Tranchant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Quetel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"De Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Meiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"De Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Le Pimpec-Barthes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Zucman-Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Jaurand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5823-7404","authenticated-orcid":false,"given":"Didier","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1-4","key":"10.1016\/j.lungcan.2018.10.015_bib0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10937404.2011.556051","article-title":"Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases","volume":"14","author":"Huang","year":"2011","journal-title":"J. Toxicol. Environ. Health B Crit. Rev."},{"key":"10.1016\/j.lungcan.2018.10.015_bib0010","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific advances and new frontiers in mesothelioma therapeutics","volume":"13","author":"Mutti","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.015_bib0015","series-title":"Malignant Pleural Mesothelioma: Present Status and Future Directions","first-page":"169","article-title":"Biomolecular pathways and malignant pleural mesothelioma","author":"Jaurand","year":"2016"},{"issue":"4","key":"10.1016\/j.lungcan.2018.10.015_bib0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.lungcan.2018.10.015_bib0025","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reynies","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2018.10.015_bib0030","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"10026","key":"10.1016\/j.lungcan.2018.10.015_bib0035","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French Cooperative Thoracic Intergroup, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.lungcan.2018.10.015_bib0040","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/13543784.2017.1351545","article-title":"Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma","volume":"26","author":"Guazzelli","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"6","key":"10.1016\/j.lungcan.2018.10.015_bib0045","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/joim.12429","article-title":"The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer","volume":"278","author":"Tobin","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.lungcan.2018.10.015_bib0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcancer.2016.09.002","article-title":"Novel biomarkers in cancer: the whole is greater than the sum of its parts","volume":"45","author":"Samatov","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.lungcan.2018.10.015_bib0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/mutage\/get008","article-title":"Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma","volume":"28","author":"Andujar","year":"2013","journal-title":"Mutagenesis"},{"issue":"28","key":"10.1016\/j.lungcan.2018.10.015_bib0060","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1038\/onc.2013.351","article-title":"Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma","volume":"33","author":"Tallet","year":"2014","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.lungcan.2018.10.015_bib0065","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ajpath.2010.10.039","article-title":"Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma","volume":"178","author":"Jean","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2018.10.015_bib0070","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ijc.2910550331","article-title":"In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines","volume":"55","author":"Zeng","year":"1993","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2018.10.015_bib0075","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/bjc.2015.60","article-title":"ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels","volume":"112","author":"Rondeau","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"237","key":"10.1016\/j.lungcan.2018.10.015_bib0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2018.10.015_bib0085","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"issue":"Database issue","key":"10.1016\/j.lungcan.2018.10.015_bib0090","first-page":"D955","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.lungcan.2018.10.015_bib0095","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/0008-5472.CAN-06-2389","article-title":"A novel small-molecule inhibitor of transforming growth factor \u03b2 type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection","volume":"67","author":"Suzuki","year":"2007","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2018.10.015_bib0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","article-title":"Molecular changes in mesothelioma with an impact on prognosis and treatment","volume":"136","author":"Jean","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2018.10.015_bib0105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jtho.2016.10.023","article-title":"Trametinib plus 4-methylumbelliferone exhibits antitumor effects by ERK blockade and CD44 downregulation and affects PD-1 and PD-L1 in malignant pleural mesothelioma","volume":"12","author":"Cho","year":"2017","journal-title":"J. Thoracic Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2018.10.015_bib0110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1947601910375273","article-title":"A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma","volume":"1","author":"Menges","year":"2010","journal-title":"Genes Cancer"},{"issue":"47","key":"10.1016\/j.lungcan.2018.10.015_bib0115","doi-asserted-by":"crossref","first-page":"76577","DOI":"10.18632\/oncotarget.10428","article-title":"Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines","volume":"7","author":"Monica","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.lungcan.2018.10.015_bib0120","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","article-title":"Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma","volume":"12","author":"Marek","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2018.10.015_bib0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","article-title":"Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy","volume":"190","author":"Schelch","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.lungcan.2018.10.015_bib0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1878-0261.12150","article-title":"A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma","volume":"12","author":"Schelch","year":"2018","journal-title":"Mol. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2018.10.015_bib0135","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bjc.2011.400","article-title":"Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin","volume":"105","author":"Giovannetti","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2018.10.015_bib0140","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1165\/rcmb.2013-0373TR","article-title":"Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas","volume":"51","author":"Sayan","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.lungcan.2018.10.015_bib0145","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-1507","article-title":"Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo","author":"Laszlo","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.lungcan.2018.10.015_bib0150","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/onc.2016.462","article-title":"Role of the PDZ-scaffold protein NHERF1\/EBP50 in cancer biology: from signaling regulation to clinical relevance","volume":"36","author":"Vaquero","year":"2017","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.lungcan.2018.10.015_bib0155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/onc.2011.245","article-title":"Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells","volume":"31","author":"Bulut","year":"2012","journal-title":"Oncogene"},{"issue":"39","key":"10.1016\/j.lungcan.2018.10.015_bib0160","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1038\/onc.2017.147","article-title":"E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells","volume":"36","author":"Kato","year":"2017","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.lungcan.2018.10.015_bib0165","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Liu-Chittenden","year":"2012","journal-title":"Genes Dev."},{"issue":"49","key":"10.1016\/j.lungcan.2018.10.015_bib0170","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1038\/onc.2012.5","article-title":"YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes","volume":"31","author":"Mizuno","year":"2012","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.lungcan.2018.10.015_bib0175","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archopht.117.9.1161","article-title":"Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study","volume":"117","author":"Miller","year":"1999","journal-title":"Arch. Ophthalmol."},{"issue":"11","key":"10.1016\/j.lungcan.2018.10.015_bib0180","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/jcmm.13182","article-title":"Targeting YAP in malignant pleural mesothelioma","volume":"21","author":"Zhang","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.lungcan.2018.10.015_bib0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-4939-1804-1_12","article-title":"Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options","volume":"1238","author":"Zhang","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"17","key":"10.1016\/j.lungcan.2018.10.015_bib0190","doi-asserted-by":"crossref","first-page":"28628","DOI":"10.18632\/oncotarget.15614","article-title":"Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells","volume":"8","author":"Dasari","year":"2017","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.lungcan.2018.10.015_bib0195","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1016\/j.yexcr.2010.08.002","article-title":"Lumican inhibits cell migration through \u03b12\u03b21 integrin","volume":"316","author":"Zeltz","year":"2010","journal-title":"Exp. Cell Res."},{"issue":"5","key":"10.1016\/j.lungcan.2018.10.015_bib0200","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ijc.30801","article-title":"Cancer-associated fibroblast-derived Lumican promotes gastric cancer progression via the integrin \u03b21-FAK signaling pathway","volume":"141","author":"Wang","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2018.10.015_bib0205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2443.1999.00261.x","article-title":"Molecular cloning and characterization of a novel member of the MAP kinase superfamily","volume":"4","author":"Miyata","year":"1999","journal-title":"Genes Cells"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T07:28:12Z","timestamp":1589959692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218305993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":41,"alternative-id":["S0169500218305993"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}